Sofosbuvir/Ledipasvir
Treatment for Acute hepatitis C
Effectiveness
97%
Safety Score
70%
Clinical Trials
3
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
0
Sofosbuvir/Ledipasvir Outcomes
for Acute hepatitis C
Efficacy Outcomes
Overall Effectiveness
+97%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
3 completed trials for Sofosbuvir/Ledipasvir in Acute hepatitis C
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
NCT02128217COMPLETEDPHASE1
44 participants
INTERVENTIONAL
San Diego, United States +11 more
Started: May 30, 2014
HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection
NCT02309918COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Berlin, Germany +19 more
Started: Nov 1, 2014
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
NCT02457611COMPLETEDPHASE2
26 participants
INTERVENTIONAL
Berlin, Germany +3 more
Started: Jun 1, 2015